Targeted Cellular Therapy Protocols for Retinitis Pigmentosa in India
Advanced regenerative support aimed at retinal preservation, slowing disease progression, and supporting cellular function.
Clinical Protocol Summary
Retinitis Pigmentosa (RP) is a progressive genetic retinal disorder leading to photoreceptor cell loss. Our specialized clinical protocol uses ethically sourced, autologous or regulatory-cleared cellular applications designed to promote neuroprotection, enhance microvascular circulation, and preserve functional vision.
Patient Eligibility & Candidacy
Criteria evaluating retinal architecture, residual photoreceptor integrity, and medical candidacy
Initial Evaluation:
- Clinically confirmed diagnosis of Retinitis Pigmentosa (Genetic panel, ERG, or OCT reports).
- Presence of residual viable retinal cells.
- Absence of uncontrolled systemic infections, severe ocular trauma, or uncontrolled glaucoma.
Observed Improvements Post-Therapy
Observed functional responses and monitored clinical endpoints
Peripheral Vision
Peripheral Vision: Gradual stabilization or modest expansion of functional visual fields.
Light Adaptation
Light Adaptation: Enhanced recovery time when transitioning between light and dark settings.
Visual Clarity
Visual Clarity: Reduction in central blurriness and improved contrast discrimination.
Disease Deceleration
Disease Deceleration: Primary target of arresting or slowing active photoreceptor degradation.
Night Vision
Night Vision: Qualitative improvements in low-light navigation for eligible stages.
Why Choose India & Our Center
Excellence in vitreo-retinal surgery, electrophysiological tracking, and affordable care
Clinical Expertise
Clinical Expertise: Procedures led by fellowship-trained retinal surgeons and regenerative medicine researchers.
Stringent Quality Standards
Stringent Quality Standards: Cleanroom processing adhering to Indian Council of Medical Research (ICMR) safety frameworks.
Cost Efficiency
Cost Efficiency: Comprehensive clinical packages at 60–75% less cost compared to North America or Western Europe.
Multimodal Rehabilitation
Multimodal Rehabilitation: Integration of ocular acupuncture, vision training, and targeted nutritional therapy.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering single or bilateral eyes based on clinical severity and cell dosage).
(Aimed at slowing visual degeneration, neurotrophic rescue, and stabilizing functional sight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | $4,500 – $7,500 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $25,000 – $45,000 USD | 3 – 6 Months | Clinical Trial Gated |
| United Kingdom & EU | $22,000 – $38,000 USD | 2 – 5 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated International Concierge Services
Comprehensive international logistics supporting patients with visual field impairment
Pre-Travel Teleconsult
Pre-Travel Teleconsult: One-on-one virtual review of ophthalmology scans with our clinical team.
Medical Visa Assistance
Medical Visa Assistance: Official medical visa invitation letters and embassy documentation support within 48 hours.
Language Support
Language Support: Dedicated multi-lingual patient coordinators (English, Arabic, Russian, French).
Airport Transfers
Airport Transfers: Complimentary airport pick-up, drop-off, and daily hospital transit.
Travel, Logistics & Accommodation
Accessible hotel partners and dedicated companion facilities
Accommodation Options
Accommodation Options: On-site private patient suites or vetted 4-star/5-star partner hotels located within 10 minutes of the clinic.
Companion Friendly
Companion Friendly: Rooms arranged for the patient and an accompanying family member or caregiver.
Dietary Arrangements
Dietary Arrangements: Custom dining plans catering to international dietary, halal, vegetarian, and therapeutic needs.
Foreign Exchange & SIM
Foreign Exchange & SIM: On-arrival assistance with local connectivity and currency exchange.
Treatment Schedule (Typical 5–7 Day Protocol)
Day-by-day clinical schedule from baseline ERG testing to safe return departure
Day 1: Arrival & Clinical Profiling
Day 1: Arrival & Clinical Profiling: Comprehensive baseline testing (Visual field, OCT, ERG, general health clearance).
Day 2: Protocol Preparation
Day 2: Protocol Preparation: Autologous harvesting/isolation (if applicable) or preparation in certified cGMP cleanroom facilities.
Days 3–4: Targeted Administration
Days 3–4: Targeted Administration: Precise, minimally invasive delivery (retrobulbar, sub-tenon, or IV infusion) under local anesthesia.
Days 5–6: Post-Procedure Monitoring
Days 5–6: Post-Procedure Monitoring: Retinal evaluation, adjunct therapies (hyperbaric oxygen/neuroprotective infusions if advised).
Day 7: Discharge & Follow-up Plan
Day 7: Discharge & Follow-up Plan: Discharge summary, home care protocol, and international tele-monitoring roadmap.
Cellular Safety Release & Quality Protocols
Adherence to international cGMP cleanroom protocols and sterility testing
cGMP Cleanroom Processing
Processed under ISO Class 5 laminar flow biosafety hoods with continuous environmental monitoring.
Flow Cytometry Verification
ISCT criteria verified: ≥95% positive CD73/CD90/CD105 and ≤2% negative CD34/CD45/HLA-DR.
14-Day Sterility Testing
Automated multi-pathogen sterility cultures, mycoplasma PCR, and LAL endotoxin testing prior to use.
Ethics Committee Governance
All procedures adhere to CDSCO-registered Institutional Ethics Committee (IEC) oversight.
Frequently Asked Questions: Retinitis Pigmentosa Care
Authoritative medical guidance regarding cellular protocols, realistic visual outcomes, and travel
Mesenchymal stem cells release neuroprotective trophic factors (such as Rod-derived Cone Viability Factor, BDNF, and GDNF) that delay apoptosis in stressed photoreceptor cells. This prolongs surviving rod-cone vitality and stabilizes the outer nuclear layer of the retina (Weiss & Levy, 2018).
No. Stem cell therapy is an investigational cytoprotective treatment rather than genetic gene therapy. It does not alter genetic mutations (like RHO or USH2A) but aims to protect existing retinal cells from premature degeneration, helping to preserve central tunnel vision.
Patients with confirmed clinical RP who retain at least 10 to 20 degrees of central visual field, measurable visual acuity, and demonstrable outer retinal structure on Spectral-Domain OCT are the best candidates.
Monitoring incorporates Full-Field Electroretinography (ffERG), Humphrey visual field (HVF 10-2 or 30-2) perimetry, microperimetry, and dark adaptometry.
Procedures are performed under local ocular anesthesia in hospital operating theaters. Injections are placed in the periocular sub-Tenon or suprachoroidal spaces without penetrating the intraocular cavity, significantly minimizing procedural risks.
The full schedule is 3 to 4 days, accommodating baseline electrophysiology assessments, bilateral cellular administration, post-procedure safety review, and travel clearance.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Retinitis Pigmentosa:
Regulatory Transparency & Medical Disclaimer
Clinical Reality
Clinical Reality: Stem cell protocols for Retinitis Pigmentosa are regenerative interventions aimed at cellular protection and stabilization; they do not constitute a definitive genetic cure. Outcomes vary depending on the patient’s stage of progression and residual retinal health.
Institutional Governance
Institutional Governance: All protocols follow strict bioethical standards, informed consent procedures, and institutional committee oversight.